Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Core Insights - Catalyst Pharmaceuticals achieved record revenues of $589 million in 2025, reflecting a 20.3% growth in net product revenue driven by enhanced patient identification and market penetration [4] - FIRDAPSE's growth was supported by a 40% increase in identified patient leads and a 12% reduction in early discontinuations due to a new pharmacy outreach program [4] - AGAMREE reached 100% penetration in top Centers of Excellence, capturing 80% of the Duchenne Muscular Dystrophy patient population [4] - The company plans to transition FYCOMPA to a non-promoted status following generic entry while still contributing to revenue [4] - Business development activity surged with over 100 assessments in 2025, with 90% being inbound inquiries [4] Strategic Performance and Operational Drivers - The company attributes its commercial success to a 'plug-and-play' infrastructure utilizing AI and machine learning to prioritize high-urgency patient leads [4] - Total revenue guidance for 2026 is set between $615 million and $645 million, assuming continued expansion in idiopathic and cancer-associated LEMS markets [4] - The strategy for FIRDAPSE in 2026 includes integrating updated NCCN guidelines into oncology care pathways to tap into the under-penetrated cancer-associated LEMS segment [4] - AGAMREE's growth is expected to deepen within existing Centers of Excellence, supported by a 5-year SUMMIT follow-up study [4] Financial Outlook - A $12.5 million milestone payment was triggered in Q4 2025 as AGAMREE's net product revenue surpassed the $100 million threshold [6] - R&D expenses are forecasted to rise to $17.5 million - $22.5 million in 2026 to support AGAMREE life cycle management and new indication assessments [6] - FYCOMPA revenue is expected to decline significantly, with 2026 guidance set at $40 million to $45 million following the cessation of active promotion [4] Legal Considerations - A patent infringement trial against Hetero USA is scheduled for March 23, 2026, to protect FIRDAPSE's intellectual property ahead of the 30-month stay expiration [4]